Our manifesto

Redefining metabolic care
for obesity and diabetes.

 

We’re building something new – in what we do, and how we do it.

 

On substance, our focus is clear: metabolic health.

 

We combine science, clinical-grade tools and AI to support patients where it matters most — starting with those on GLP-1s for obesity and diabetes.

 

Because these treatments open a rare window for change, and we’re here to make it count.

 

On structure, we’re building an AI-native company – lean, fast, and impact-driven. Small teams. Sharp focus. Every process optimized to deliver real results.

 

We don’t do theatre. We build.
No hype. No ego. Just work that matters.

 

We’ve done it before. This time, it’s bigger.

 

The right science. The right moment.

 

This is Boli.

 

Meet Our Founders

Combining entrepreneurial agility with clinical-grade execution, our leadership team has built and scaled digital therapeutics platforms globally – driving adoption through B2B and B2C channels, from health plans to direct-to-patient models.

 

Paul-Louis BELLETANTE
CEO
Yan JURADO

CTO

Edouard MARTINET

CPO

Contact us

We are a european company mainly based in Biarritz, France.

Contact us for any query at [email protected]

 

From GLP-1 support to sustainable health.


A new era for obesity and diabetes care.

 

Boli is an AI-native digital therapeutic helping patients on GLP-1 treatments manage side effects, improve adherence, and achieve lasting metabolic health.

 

We’re outcomes-driven, science-based – and building a whole new kind of company.

© Boli, 2025. All rights reserved. | Medical device in development — not yet available for clinical use.